BAJAJ HEALTHCARE LIMITED Bajaj HealthCare Limited Share Price NSE India S.E.
Equities
BAJAJHCARE
INE411U01027
Pharmaceuticals
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 288.9 INR | -0.87% |
|
-4.70% | -23.16% |
| Sales 2022 | 6.8B 81.51M 6.4B | Sales 2023 | 6.73B 80.72M 6.34B | Capitalization | 8.41B 101M 7.91B |
|---|---|---|---|---|---|
| Net income 2022 | 714M 8.56M 672M | Net income 2023 | 430M 5.16M 405M | EV / Sales 2022 | 1.76 x |
| Net Debt 2022 | 2.55B 30.54M 2.4B | Net Debt 2023 | 3.98B 47.66M 3.74B | EV / Sales 2023 | 1.84 x |
| P/E ratio 2022 |
13.2
x | P/E ratio 2023 |
19.5
x | Employees | 1,173 |
| Yield 2022 |
0.44% | Yield 2023 |
0.33% | Free-Float | 25.05% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.87% | ||
| 1 week | -4.70% | ||
| 1 month | -11.29% | ||
| 3 months | -13.83% | ||
| 6 months | -25.57% | ||
| Current year | -23.16% |
1 week
286.15
308.25
1 month
286.15328.90
Current year
286.15389.00
1 year
275.70513.40
3 years
257.45513.40
5 years
257.45513.40
10 years
257.45513.40
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 49 | 14/01/04 | |
| Chief Executive Officer | 64 | 14/07/93 | |
Nandkumar Soni
COO | Chief Operating Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 58 | 13/06/23 | |
| Chief Executive Officer | 64 | 14/07/93 | |
| Director/Board Member | 38 | 10/01/13 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 31/05/24 | 288.9 | -0.87% | 55,978 |
| 30/05/24 | 291.4 | -1.40% | 32,195 |
| 29/05/24 | 295.6 | -0.76% | 32,639 |
| 28/05/24 | 297.8 | +0.44% | 29,613 |
| 27/05/24 | 296.6 | -2.18% | 132,779 |
Delayed Quote NSE India S.E., May 31, 2024 at 12:43 pm
More quotes
Bajaj Healthcare Limited is an India-based pharmaceutical company. The Company is engaged in activities of manufacturing, producing, developing and marketing a range of active pharmaceutical ingredients (APIs), bulk drugs, branded and generic formulations. Its segments include Bulk Drugs and Formulations. It is focused on development, manufacturing and supply of amino acids, nutritional supplements and API for pharmaceutical, nutraceuticals and food industries. Its APIs include ascorbic acid, CH Base and its derivatives, citicoline sodium, carbamazepine, theobromine, ferrous ascorbate, doxofylline, oxcarbazepine, choline bitartrate and its derivatives, octenidine dihydrochloride, vildagliptin, ticagrelor, diosmin, hesperidin and others. Its FDFs include Cellin 500, Septran DS Tablet, Vitajaj C tables 500mg, Ticajaj 90 tablets, Ecojaj 75mg & 150mg, Deferajaj 400mg & 500mg, Vildajaj 50mg and Vildajaj M 50/500. It also offers Inositol Nicotinate and Magnesium L-Threonate.
Sector
Pharmaceuticals
Calendar
12/08/2024
- Q1 2025 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +40.73% | 739B | |
| +32.83% | 598B | |
| -6.30% | 353B | |
| +15.15% | 318B | |
| +4.05% | 285B | |
| +15.00% | 240B | |
| +9.78% | 210B | |
| -5.52% | 206B | |
| +6.17% | 164B |
- Stock Market
- Equities
- BAJAJHCARE Stock
- BAJAJHCARE Stock
